167 related articles for article (PubMed ID: 16899618)
1. Intratumoral therapy with IL13-PE38 results in effective CTL-mediated suppression of IL-13Ralpha2-expressing contralateral tumors.
Kawakami K; Terabe M; Kioi M; Berzofsky JA; Puri RK
Clin Cancer Res; 2006 Aug; 12(15):4678-86. PubMed ID: 16899618
[TBL] [Abstract][Full Text] [Related]
2. IL-13 cytotoxin has potent antitumor activity and synergizes with paclitaxel in a mouse model of oral squamous cell carcinoma.
Kioi M; Shimamura T; Nakashima H; Hirota M; Tohnai I; Husain SR; Puri RK
Int J Cancer; 2009 Mar; 124(6):1440-8. PubMed ID: 19065664
[TBL] [Abstract][Full Text] [Related]
3. Analysis of antitumor activity of an interleukin-13 (IL-13) receptor-targeted cytotoxin composed of IL-13 antagonist and Pseudomonas exotoxin.
Kioi M; Kawakami K; Puri RK
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6231-8. PubMed ID: 15448012
[TBL] [Abstract][Full Text] [Related]
4. Specifically targeted killing of interleukin-13 (IL-13) receptor-expressing breast cancer by IL-13 fusion cytotoxin in animal model of human disease.
Kawakami K; Kawakami M; Puri RK
Mol Cancer Ther; 2004 Feb; 3(2):137-47. PubMed ID: 14985454
[TBL] [Abstract][Full Text] [Related]
5. Combined effects of radiation and interleukin-13 receptor-targeted cytotoxin on glioblastoma cell lines.
Kawakami K; Kawakami M; Liu Q; Puri RK
Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):230-7. PubMed ID: 16111594
[TBL] [Abstract][Full Text] [Related]
6. IL-13 receptor-targeted cytotoxin cancer therapy leads to complete eradication of tumors with the aid of phagocytic cells in nude mice model of human cancer.
Kawakami K; Kawakami M; Puri RK
J Immunol; 2002 Dec; 169(12):7119-26. PubMed ID: 12471149
[TBL] [Abstract][Full Text] [Related]
7. Interleukin 13 mediates signal transduction through interleukin 13 receptor alpha2 in pancreatic ductal adenocarcinoma: role of IL-13 Pseudomonas exotoxin in pancreatic cancer therapy.
Shimamura T; Fujisawa T; Husain SR; Joshi B; Puri RK
Clin Cancer Res; 2010 Jan; 16(2):577-86. PubMed ID: 20068108
[TBL] [Abstract][Full Text] [Related]
8. Adenoviral vector-mediated gene transfer of IL-13Ralpha2 chain followed by IL-13 cytotoxin treatment offers potent targeted therapy for cytotoxin-resistant cancers.
Saito M; Murata T; Watanabe K; Kawakami K; Suzuki M; Koji T; Puri RK; Kitazato K; Kobayashi N
Int J Cancer; 2005 Aug; 116(1):1-8. PubMed ID: 15756691
[TBL] [Abstract][Full Text] [Related]
9. Targeting IL-13Ralpha2-positive cancer with a novel recombinant immunotoxin composed of a single-chain antibody and mutated Pseudomonas exotoxin.
Kioi M; Seetharam S; Puri RK
Mol Cancer Ther; 2008 Jun; 7(6):1579-87. PubMed ID: 18566228
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a novel human tumor antigen interleukin-13 receptor alpha2 chain.
Kawakami K; Terabe M; Kawakami M; Berzofsky JA; Puri RK
Cancer Res; 2006 Apr; 66(8):4434-42. PubMed ID: 16618770
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral interleukin-21 increases antitumor immunity, tumor-infiltrating CD8+ T-cell density and activity, and enlarges draining lymph nodes.
Søndergaard H; Galsgaard ED; Bartholomaeussen M; Straten PT; Odum N; Skak K
J Immunother; 2010 Apr; 33(3):236-49. PubMed ID: 20445344
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-13 receptor-targeted cancer therapy in an immunodeficient animal model of human head and neck cancer.
Kawakami K; Kawakami M; Joshi BH; Puri RK
Cancer Res; 2001 Aug; 61(16):6194-200. PubMed ID: 11507072
[TBL] [Abstract][Full Text] [Related]
13. Synergistic effect of intratumoral IL-12 and TNF-alpha microspheres: systemic anti-tumor immunity is mediated by both CD8+ CTL and NK cells.
Sabel MS; Arora A; Su G; Mathiowitz E; Reineke JJ; Chang AE
Surgery; 2007 Nov; 142(5):749-60. PubMed ID: 17981196
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic modulation enhances the therapeutic effect of anti-IL-13R(alpha)2 antibody in human mesothelioma xenografts.
Takenouchi M; Hirai S; Sakuragi N; Yagita H; Hamada H; Kato K
Clin Cancer Res; 2011 May; 17(9):2819-29. PubMed ID: 21357681
[TBL] [Abstract][Full Text] [Related]
15. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells.
Kahlon KS; Brown C; Cooper LJ; Raubitschek A; Forman SJ; Jensen MC
Cancer Res; 2004 Dec; 64(24):9160-6. PubMed ID: 15604287
[TBL] [Abstract][Full Text] [Related]
16. Transforming growth factor-alpha-Pseudomonas exotoxin fusion protein (TGF-alpha-PE38) treatment of subcutaneous and intracranial human glioma and medulloblastoma xenografts in athymic mice.
Phillips PC; Levow C; Catterall M; Colvin OM; Pastan I; Brem H
Cancer Res; 1994 Feb; 54(4):1008-15. PubMed ID: 8313355
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-13 receptor alpha2 chain: a potential biomarker and molecular target for ovarian cancer therapy.
Kioi M; Kawakami M; Shimamura T; Husain SR; Puri RK
Cancer; 2006 Sep; 107(6):1407-18. PubMed ID: 16902988
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-13 receptor as a unique target for anti-glioblastoma therapy.
Husain SR; Joshi BH; Puri RK
Int J Cancer; 2001 Apr; 92(2):168-75. PubMed ID: 11291041
[TBL] [Abstract][Full Text] [Related]
19. Potent antitumor activity of IL-13 cytotoxin in human pancreatic tumors engineered to express IL-13 receptor alpha2 chain in vivo.
Kawakami K; Kawakami M; Husain SR; Puri RK
Gene Ther; 2003 Jul; 10(13):1116-28. PubMed ID: 12808442
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneity in interleukin-13 receptor expression and subunit structure in squamous cell carcinoma of head and neck: differential sensitivity to chimeric fusion proteins comprised of interleukin-13 and a mutated form of Pseudomonas exotoxin.
Joshi BH; Kawakami K; Leland P; Puri RK
Clin Cancer Res; 2002 Jun; 8(6):1948-56. PubMed ID: 12060640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]